Navigation Links
Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results
Date:1/10/2013

ations for two weeks during the quarter for the Thanksgiving, Christmas and New Year holidays as part of our cost reduction program.  Our backlog is strong for the second half of fiscal 2013.  We expect to continue to press down on our cost structure while increasing engineering resources.  We expect the programs and projects that we have begun to move our company forward and to build value for every shareholder."

"Of course," Mr. Berthelot noted, "we appreciate the support of each and every shareholder as we pursue our strategy amidst the distraction and diversion of resources due to the contested election of directors.  We understand that there have been some logistical problems in our proxy materials arriving to our shareholders on the West Coast.  If you have not yet received the Company's proxy materials which include the BLUE proxy card, we encourage you to contact our proxy solicitor, AST Phoenix Advisers, at 1-866-721-1318 and ask for the materials to be sent to you.  We ask that all of our shareholders vote for the Pro-Dex director nominees using the BLUE proxy card as quickly as possible, and we thank you for your support."

Teleconference Information:Investors and analysts are invited to listen to a broadcast review of the Company's fiscal 2013 second quarter and six-month financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company's website at www.pro-dex.com.  The conference call may also be accessed at www.InvestorCalendar.com. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available approximately two hours after the completion of the call until midnight (Ea
'/>"/>

SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results
2. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
3. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
4. Pro-Dex, Inc. Announces Update Conference Call and Webcast
5. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
7. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
8. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
9. Accelr8 Announces Results of 2012 Annual Meeting
10. OncoSec Medical Announces $7.2 Million Public Offering
11. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... 2014 The American Society ... professionals engaged in the field of organ transplantation, ... and Immunology Research Network (TIRN), a professional ... As modern organ transplantation continues to diversify, AST ... provide more opportunities for physicians, scientists and researchers ...
(Date:7/28/2014)... developed at University of Colorado Skaggs School of Pharmacy ... 28, 2014) An influential new test, discovered and ... CU School of Pharmacy, helps monitor the effectiveness of ... tenofovir/emtricitabine), which is taken once daily to prevent HIV ... 2014 Conference and published in Lancet Infectious Diseases ...
(Date:7/28/2014)... 2014 Drorit Silverman, a professional bodybuilder ... to raise investment capital through her crowd funding camping ... the United States. , According to a statement released ... centers provide a great window of opportunity for investors ... In addition to this, Silverman looks at the 24/7 ...
(Date:7/28/2014)... "Fist bumping" transmits significantly fewer bacteria than ... cultural expectation of hand-to-hand contact between patients and ... August issue of the American Journal of ... Association for Professionals in Infection Control and Epidemiology ... of Biological, Environmental, and Rural Sciences at Aberystwyth ...
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and segments ... of revenue. The Wireline services market in Europe is estimated ... billion by 2019, at a CAGR of 11.2%, for the ... Services Market in Europe report, to get an idea of ... the segmentation in the European Wireline Services market, and is ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4
... men treated with a combination of radiation seed implants ... cured of their disease 15 years// following their treatment, ... Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. ... at the Seattle Prostate Institute. Doctors wanted to look ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... alleviate symptoms of early-stage Parkinson's disease, and may be ... the brain disorder,// researchers said., ,A neupro patch ... to study its effects on 277 people in Canada ... is designed to convey a drug called rotigotine ...
... Parkinson's appear to increase the risk of heart valve disease, ... disorder of the central nervous system that often impairs motor ... that keep blood flowing in the right direction through the ... blood may not move the way it should., ,The ...
... is the final awakening' - Walter Scott// ... the former president of Iraq, Saddam Hussein, was sent to the ... the fact that he slaughtered 148 fellow countrymen, who were Shias, ... put to use in all societies to wipe out political dissent. ...
... Inner city dwellings were thought to be far cleaner and ... say this is not true- inner cities are a haven// ... and TNS analyzed smoking and disease rates and dietary habits ... The analysis revealed that towns such as Merthyr Tydfil in ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: